Galapagos reaps $46M payday as GSK preps PhII study

Belgium's Galapagos NV says that GlaxoSmithKline ($GSK) is prepping a Phase II study of GSK2586184 (formerly GLPG0778)--its JAK1 inhibitor--for ulcerative colitis. The advance triggers a $46 million milestone payday for Galapagos, which partnered with GSK on the program in early 2012. "Galapagos has discovered multiple JAK inhibition molecules, three of which have reached the clinic," said Onno van de Stolpe, CEO of Galapagos. Release

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.